Fenwick Represents Umoja Biopharma in $100 Million Series C Financing

Fenwick represented Umoja Biopharma, Inc., a developer of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, in its $100 million Series C financing. The round new and existing prominent life science investors.

The proceeds from this financing will enable Umoja to advance its in vivo CAR T cell therapy pipeline, including its lead CD22 UB-VV400 program in multiple oncology and autoimmune clinical studies. More information can be obtained from Umoja’s announcement.

The Fenwick transaction team was led by corporate partner Ryan McRobert and included associates Adam Conway, Lindsey Macalalad, and Ben Enos.